146 related articles for article (PubMed ID: 34314015)
1. Neurofunctional outcomes in patients with anti-leucine-rich glioma inactivated 1 encephalitis.
Chen W; Wang M; Gao L; Huang Z; Lin Y; Xue Q; Liu G; Zhang Y; Su Y
Acta Neurol Scand; 2021 Dec; 144(6):632-639. PubMed ID: 34314015
[TBL] [Abstract][Full Text] [Related]
2. CHI3L1 in the CSF is a potential biomarker for anti-leucine-rich glioma inactivated 1 encephalitis.
Li J; Li H; Wang Y; Zhao X; Wang S; Li L
Front Immunol; 2022; 13():1071219. PubMed ID: 36685530
[TBL] [Abstract][Full Text] [Related]
3. Neurological, psychiatric, and sleep investigations after treatment of anti-leucine-rich glioma-inactivated protein 1 (LGI1) encephalitis in Spain: a prospective cohort study.
Muñoz-Lopetegi A; Guasp M; Prades L; Martínez-Hernández E; Rosa-Justícia M; Patricio V; Armangué T; Rami L; Borràs R; Castro-Fornieles J; Compte A; Gaig C; Santamaria J; Dalmau J;
Lancet Neurol; 2024 Mar; 23(3):256-266. PubMed ID: 38365378
[TBL] [Abstract][Full Text] [Related]
4. Clinical Features, Immunotherapy, and Outcomes of Anti-Leucine-Rich Glioma-Inactivated-1 Encephalitis.
Huang X; Fan C; Gao L; Li L; Ye J; Shen H
J Neuropsychiatry Clin Neurosci; 2022; 34(2):141-148. PubMed ID: 34794327
[TBL] [Abstract][Full Text] [Related]
5. Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis.
Sola-Valls N; Ariño H; Escudero D; Solana E; Lladó A; Sánchez-Valle R; Blanco Y; Saiz A; Dalmau J; Graus F
Neurol Neuroimmunol Neuroinflamm; 2020 Mar; 7(2):. PubMed ID: 31848230
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of anti-leucine-rich glioma-inactivated 1 encephalitis in northeast China.
Zhao Q; Sun L; Zhao D; Chen Y; Li M; Lu Y; Li G; Lin W
Clin Neurol Neurosurg; 2021 Apr; 203():106542. PubMed ID: 33706063
[TBL] [Abstract][Full Text] [Related]
7. Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis.
Campetella L; Farina A; Villagrán-García M; Villard M; Benaiteau M; Timestit N; Vogrig A; Picard G; Rogemond V; Psimaras D; Rafiq M; Chanson E; Marchal C; Goncalves D; Joubert B; Honnorat J; Muñiz-Castrillo S
Neurol Neuroimmunol Neuroinflamm; 2024 May; 11(3):e200228. PubMed ID: 38603771
[TBL] [Abstract][Full Text] [Related]
8. Clinical features and outcomes of leucine-rich glioma-inactivated protein 1 and contactin protein-like 2 antibody-associated autoimmune encephalitis in a Chinese cohort.
Li HY; Qiao S; Cui CS; Feng F; Liu XW; Yang XD
J Clin Neurosci; 2022 Jul; 101():137-143. PubMed ID: 35597061
[TBL] [Abstract][Full Text] [Related]
9. [Clinical features and outcomes in relapsing and monophasic patients with anti-leucine-rich glioma-inactivated 1 encephalitis].
Li JM; Ma XR; Peng T; Li JH; Lu H
Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(25):1947-1951. PubMed ID: 32629594
[No Abstract] [Full Text] [Related]
10. Seizures and risk of epilepsy in anti-NMDAR, anti-LGI1, and anti-GABA
Shen CH; Fang GL; Yang F; Cai MT; Zheng Y; Fang W; Guo Y; Zhang YX; Ding MP
Ann Clin Transl Neurol; 2020 Aug; 7(8):1392-1399. PubMed ID: 32710704
[TBL] [Abstract][Full Text] [Related]
11. Acute Symptomatic Seizures and Risk of Seizure Recurrence in Patients with Anti-NMDAR, Anti-LGI1, and Anti-GABA
Cui D; Feng J; Yang M; Dong Y; Lian Y
Neurol Sci; 2024 Apr; 45(4):1609-1617. PubMed ID: 37940748
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil reduces the risk of relapse in anti-leucine-rich glioma-inactivated protein 1 encephalitis: a prospective observational cohort study.
Liu M; Xu X; Fan S; Ren H; Zhao Y; Guan H
Neurol Sci; 2024 Jan; 45(1):253-260. PubMed ID: 37580515
[TBL] [Abstract][Full Text] [Related]
13. Predicting the functional outcomes of anti-LGI1 encephalitis using a random forest model.
Li G; Liu X; Wang M; Yu T; Ren J; Wang Q
Acta Neurol Scand; 2022 Aug; 146(2):137-143. PubMed ID: 35373330
[TBL] [Abstract][Full Text] [Related]
14. Clinical features of nine cases of leucine-rich glioma inactivated 1 protein antibody-associated encephalitis.
Li Y; Song F; Liu W; Wang Y
Acta Neurol Belg; 2021 Aug; 121(4):889-897. PubMed ID: 32232701
[TBL] [Abstract][Full Text] [Related]
15. Status epilepticus associated with acute encephalitis: long-term follow-up of functional and cognitive outcomes in 72 patients.
Chen W; Su Y; Jiang M; Liu G; Tian F; Ren G
Eur J Neurol; 2018 Oct; 25(10):1228-1234. PubMed ID: 29751371
[TBL] [Abstract][Full Text] [Related]
16. [Clinical analysis of 9 cases with Anti-leucine-rich glioma inactivated 1 protein antibody associated limbic encephalitis].
Zhang YX; Yang HL; Wu YY; Wang CC; Gao XY; Shi YY; Liu HQ; Huang Y; Zhang JW
Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1295-1298. PubMed ID: 28482428
[No Abstract] [Full Text] [Related]
17. Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies - a national cohort study.
Celicanin M; Blaabjerg M; Maersk-Moller C; Beniczky S; Marner L; Thomsen C; Bach FW; Kondziella D; Andersen H; Somnier F; Illes Z; Pinborg LH
Eur J Neurol; 2017 Aug; 24(8):999-1005. PubMed ID: 28544133
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and short-term prognosis of LGI1 antibody encephalitis: a retrospective case study.
Li W; Wu S; Meng Q; Zhang X; Guo Y; Cong L; Cong S; Zheng D
BMC Neurol; 2018 Jul; 18(1):96. PubMed ID: 29980179
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies.
Finke C; Prüss H; Heine J; Reuter S; Kopp UA; Wegner F; Then Bergh F; Koch S; Jansen O; Münte T; Deuschl G; Ruprecht K; Stöcker W; Wandinger KP; Paul F; Bartsch T
JAMA Neurol; 2017 Jan; 74(1):50-59. PubMed ID: 27893017
[TBL] [Abstract][Full Text] [Related]
20. Electroencephalographic findings in antileucine-rich glioma-inactivated 1 (LGI1) autoimmune encephalitis: A systematic review.
Roberto KT; Espiritu AI; Fernandez MLL; Gutierrez JC
Epilepsy Behav; 2020 Nov; 112():107462. PubMed ID: 32971385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
